Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the "Stock Exchange") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Biostime International Holdings Limited

合生元國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1112)

(1) COMPLETION OF A MAJOR TRANSACTION IN RELATION TO THE ACQUISITION OF AN APPROXIMATELY 83% EQUITY INTEREST IN SWISSE WELLNESS GROUP PTY LTD; AND (2) DELAY IN DESPATCH OF CIRCULAR

Sole Financial Adviser to the Company



Unless otherwise defined in this announcement, terms defined in the announcement dated 17 September 2015 (the "Announcement") issued by Biostime International Holdings Limited (the "Company") have the same meanings when used in this announcement.

COMPLETION OF THE ACQUISITION OF AN APPROXIMATELY 83% EOUITY INTEREST IN SWISSE WELLNESS GROUP PTY LTD

The Board is pleased to announce that the conditions precedent to the Acquisition have been fulfilled and completion of the Acquisition took place on 30 September 2015. As a result, the Purchaser has successfully acquired an approximately 83% equity interest in the Target Company and the Target Company is now an indirect subsidiary of the Company and, accordingly, the financial information of the Target Group will be consolidated into the accounts of the Group.

Subject to the post-completion adjustments described in the Announcement, the total cash consideration paid by the Purchaser to the Sellers for the Acquisition was approximately AUD1,213 million (equivalent to approximately HKD6,533 million).

In addition to the cash consideration for the Acquisition, the Company issued the Consideration Shares to the Sellers on completion of the Acquisition at an issue price of HKD13.48 each. The Consideration Shares represent approximately 3.3% of the issued share capital of the Company immediately after completion of the Acquisition and as enlarged by the issue of the Consideration Shares.

DELAY IN DESPATCH OF CIRCULAR

Under Rule 14.41(a) of the Listing Rules, the Company is required to despatch the circular containing, among other things, (i) details of the Acquisition; (ii) financial and other information of the Target Group; (iii) certain pro forma financial information of the Group combined with that of the Target Group; and (iv) other information as required under the Listing Rules (the "Circular") within 15 business days after publication of the Announcement. As disclosed in the Announcement, the Company had expected to despatch the Circular to Shareholders on or before 12 October 2015. However, additional time is required to prepare and finalise the accountants' report on the Target Group to be included in the Circular, and this report is not expected to be finalised until 22 October 2015. Accordingly, the Company has applied for, and the Stock Exchange has granted, a waiver from strict compliance with Rule 14.41(a) of the Listing Rules such that the time limit for despatching the Circular has been extended to 9 November 2015.

Yours faithfully,
By order of the Board
Biostime International Holdings Limited
Luo Fei
Chairman

Hong Kong, 30 September 2015

For the purposes of this announcement, conversion of AUD into HKD is calculated at the exchange rate of AUD1:HKD5.3856. This exchange rate is for illustrative purpose only and does not constitute a representation that any amount has been, could have been, or may be exchanged at this or any other rate or at all.

As at the date of this announcement, the executive Directors of the Company are Mr. Luo Fei and Ms. Kong Qingjuan; the non-executive Directors of the Company are Dr. Zhang Wenhui, Mr. Wu Xiong, Mr. Luo Yun and Mr. Chen Fufang; and the independent non-executive Directors of the Company are Dr. Ngai Wai Fung, Mr. Tan Wee Seng and Professor Xiao Baichun.